Exact Sciences could rise 50%, Barron's says Exact Sciences shares could rise 50% fit the company's colon cancer test ramps up quickly, Barron's contends in a feature article. Short sellers are betting heavily against the company, the paper adds. Reference Link
Exact Sciences price target lowered to $26 from $32 at Canaccord Canaccord lowered its price target on Exact Sciences to $26 from $32 to reflect dilution of the large secondary offering. The firm maintains its Buy rating on Exact Sciences shares, citing its sales force expansion, payer traction and a high probability of a positive outcome from the USPSTF decision.